CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
Recruiting · NCT06209619 · Registry updated 2026-02-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | B-Cell Non-Hodgkin Lymphoma-Recurrent; B-Cell Non-Hodgkin Lymphoma-Refractory; Diffuse Large B-Cell Lymphoma-Recurrent; Diffuse Large B-Cell Lymphoma-Refractory; Follicular Lymphoma-Recurrent; Follicular Lymphoma-Refractory; High Grade B-Cell Lymphoma-Recurrent; High Grade B-Cell Lymphoma-Refractory; Primary Mediastinal Large B-Cell Lymphoma-Recurrent; Primary Mediastinal Large B-Cell Lymphoma-Refractory; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Refractory | Recruiting | Phase 1 | 2026-02-27 | NCT06209619 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Nathan Denlinger | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ohio State University Comprehensive Cancer Center | Columbus | United States | 548 |